Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHTCF.L Regulatory News (HTCF)

  • There is currently no data for HTCF

Performance Update

17 Nov 2015 14:30

RNS Number : 0291G
BlueCrest AllBlue Fund Ltd
17 November 2015
 



FOR IMMEDIATE RELEASE

 

17 November 2015

 

BLUECREST ALLBLUE FUND LIMITED

FACTSHEET - OCTOBER 2015

 

"BlueCrest AllBlue delivered continued solid performance"

 

BlueCrest AllBlue Fund Limited (BCAB) delivered continued solid performance of 0.4% in October, bringing the gain for the year to date to 3.2% (Sterling Class NAV). The rolling 12 month return rose to 4.6% and volatility, at 3.1%, remained stable around historic norms.

 

Investor sentiment improved notably as October progressed and by month end, equity markets had produced strong gains, credit spreads had tightened and commodities had stabilised. However, markets seemed driven more by better sentiment than hard data as economic data were generally mixed and there were no changes to central bank policy, although the ECB hinted at an expansion of quantitative easing.

 

"Three of the seven strategies were positive"

 

Three of the seven strategies were positive in October, with the strongest performance coming from BlueCrest Quantitative Equity, up 1.8% for the month. BlueCrest Emerging Markets, BlueCrest Mercantile and BlueCrest Equity Strategies all posted small losses.

 

In October, BlueCrest Quantitative Equity produced strong returns as gains were seen across all regions, although Europe accounted for the majority of performance. Proprietary signals outperformed, with the European alpha capture signal being a strong contributor. As usual, net exposure remained tightly controlled around zero both overall and at a regional level.

BlueCrest Capital International also had another good month as opportunities in the fixed interest markets remain fruitful. Gains were derived principally from European trading and in cross market strategies, as divergent regional monetary policies continue to offer good trading opportunities. European trading benefitted from a long bias to European rates, positioning in dollar/euro and also from European curve steepeners. In North America, US relative value trading and Canadian curve flattening trades were also profitable, although mortgage trading detracted.

 

The principle detractor was BlueTrend 2x which fell by 3.8% in the month. Clearly the magnitude of BlueTrend 2x's performance is much larger than the prior unleveraged allocation, with the position size halved accordingly. Therefore, the impact at the AllBlue level is not magnified. BlueTrend saw six of its seven strategies produce negative returns with only the net short position in energy being positive. The model had to contend with sharp reversals early in the month and in some strategies such as equities, switched orientation accordingly. VaR levels finished October down slightly, although exposure to agriculture and energy increased.

 

No changes were made to allocations between the seven funds for November.

 

"It is likely that a continuation vote will be triggered"

 

The Company's discount remained stable during the month at a little over 5%, with the Company buying shares periodically. That said, the Company has outperformed its listed peer group, which are generally trading on wider discounts. It is likely that a continuation vote will be triggered in the near term in the Sterling shares and the Board will communicate with shareholders in the event that this occurs.

 

In January 2015, BlueCrest spun out the management of part of its systematic business into Systematica Investments, in which BlueCrest retained a stake. BlueCrest recently disposed of the majority of that holding; this does not impact the ability of AllBlue to invest into BlueTrend nor the AllBlue committee's access to information necessary to make its allocation decisions.

 

 

Disclaimer:

This document is directed only at: (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; or (ii) high net worth bodies corporate, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and persons who receive this document who do not fall within (i) or (ii) above should not rely on or act upon this document.

 

This document is issued by BlueCrest AllBlue Fund Limited (the "Company") to and for the information of its existing shareholders and does not in any jurisdiction constitute investment advice or an invitation to invest in the shares or any other securities of the Company or any other entity (body corporate or otherwise).

 

The Company has used reasonable care to ensure that the information included in this document is accurate at the date of its issue, but does not undertake to update or revise the information, including any information relating to AllBlue Limited and its underlying funds (the "Funds") provided by BlueCrest Capital Management (UK) LLP or any member of the BlueCrest group of companies (as applicable) ("BlueCrest"), or guarantee the accuracy of such information. To the extent permitted by law neither the Company, the Funds, BlueCrest nor their directors or officers shall be liable for any loss or damage that anyone may suffer in reliance on such information.

 

The information in this document may be changed by the Company at any time. Past performance cannot be relied on as a guide to future performance. The Company's investment strategy is speculative and entails substantial risks. The value of an investment may go down as well as up and some or all of the total amount invested may be lost. This document may not, in whole or in part, directly or indirectly, be taken, transmitted or distributed into the United States of America, its territories or possessions or made available to any national, resident or citizen of the United States of America or any other jurisdiction where applicable laws prohibit its release, distribution or publication. Any failure to comply with these restrictions may be a violation of the law in relevant jurisdictions.

 

JTC (Guernsey) Limited

Secretary

 

Tel: Guernsey 01481 702400

 

END OF ANNOUNCEMENT

E&OE - in transmission

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRMMMMMDNVGKZM
Date   Source Headline
25th Feb 20161:15 pmRNSNet Asset Value(s)
25th Feb 201610:30 amRNSNet Asset Value(s)
24th Feb 20166:33 pmRNSResults of EGM and Cash Exit
18th Feb 20162:30 pmRNSUpdate re Return of Capital
18th Feb 201612:30 pmRNSNet Asset Value(s)
18th Feb 20169:45 amRNSHolding(s) in Company
12th Feb 20166:30 pmRNSCorrection to Form of Proxy
10th Feb 20165:30 pmRNSNet Asset Value(s)
9th Feb 20162:15 pmRNSNet Asset Value(s)
8th Feb 20164:10 pmRNSPublication of Circular
4th Feb 20164:15 pmRNSNet Asset Value(s)
4th Feb 201610:00 amRNSDirectorate Change
2nd Feb 20162:00 pmRNSUpdate on Continuation Proposals
29th Jan 20166:00 pmRNSTotal Voting Rights
27th Jan 201612:01 pmRNSHolding(s) in Company
27th Jan 201611:50 amRNSNet Asset Value(s)
25th Jan 20162:30 pmRNSUpdate on Continuation Proposals
21st Jan 20165:20 pmRNSNet Asset Value(s)
14th Jan 201611:00 amRNSNet Asset Value(s)
14th Jan 20167:00 amRNSUpdate on Continuation Proposals
12th Jan 201612:00 pmRNSTotal Voting Rights - Corrective Announcement
6th Jan 20164:45 pmRNSNet Asset Value(s)
4th Jan 20167:00 amRNSTotal Voting Rights
31st Dec 20151:30 pmRNSDirector's Other Directorship
30th Dec 20156:00 pmRNSNet Asset Value(s)
23rd Dec 20155:00 pmRNSNet Asset Value(s)
22nd Dec 201512:00 pmRNSNet Asset Value(s)
17th Dec 20157:00 amRNSFACTSHEET - NOVEMBER 2015
16th Dec 20153:30 pmRNSNet Asset Value(s)
10th Dec 20157:00 amRNSNet Asset Value(s)
9th Dec 20155:30 pmRNSUpdate on Proposed Return of Capital
8th Dec 20156:30 pmRNSHolding(s) in Company
3rd Dec 20156:20 pmRNSNet Asset Value(s)
3rd Dec 20155:30 pmRNSHolding(s) in Company
3rd Dec 20155:30 pmRNSHolding(s) in Company
3rd Dec 20154:00 pmRNSConversion between share classes
2nd Dec 20154:05 pmRNSUpdate on Proposed Return of Capital
1st Dec 20151:20 pmRNSReturn of Capital
1st Dec 201512:15 pmRNSTotal Voting Rights
30th Nov 20155:40 pmRNSTransaction in Own Shares
27th Nov 20156:20 pmRNSTransaction in Own Shares
26th Nov 20155:30 pmRNSTransaction in Own Shares
25th Nov 20155:40 pmRNSTransaction in Own Shares
25th Nov 20151:45 pmRNSNet Asset Value(s)
24th Nov 20155:45 pmRNSTransaction in Own Shares
23rd Nov 20155:45 pmRNSTransaction in Own Shares
20th Nov 20155:30 pmRNSTransaction in Own Shares
20th Nov 20153:15 pmRNSNet Asset Value(s)
20th Nov 20157:00 amRNSStatement re Continuation Vote
19th Nov 20156:00 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.